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 Abstract 62 
ADP-ribosylation, the addition of poly-ADP ribose (PAR onto proteins), is a response signal to 63 
cellular challenges, such as excitotoxicity or oxidative stress. This process is catalyzed by a 64 
group of enzymes, referred to as Poly(ADP-ribose) polymerases (PARPs). As accumulation of 65 
proteins with this modification results in cell death, its negative regulation is for cellular 66 
homeostasis: a process that is mediated by poly-ADP ribose glycohydrolases (PARGs) and 67 
ADP-ribosylhydrolase proteins (ARHs). Using genome-wide linkage analysis or exome 68 
sequencing, we identified recessive inactivating mutations in ADPRHL2 in six families. Affected 69 
individuals exhibited a pediatric-onset neurodegenerative disorder with progressive brain 70 
atrophy, developmental regression, and seizures that correlated with periods of stress such as 71 
infections. Loss of the Drosophila paralogue parg showed lethality in response to oxidative 72 
challenge that was rescued by human ADPRHL2, suggesting functional conservation. 73 
Pharmacological inhibition of PARP also rescued the phenotype, suggesting the possibility of 74 
postnatal treatment for this genetic condition.  75 
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 ADP-ribosylation is a tightly regulated posttranslational modification of proteins involved 96 
in various essential physiological and pathological processes, including DNA repair, 97 
transcription, telomere function, and apoptosis1-3. Addition of poly-ADP-ribose (PAR) is 98 
mediated by a group of enzymes, referred to as Poly(ADP-ribose) polymerases (PARPs), in 99 
response to cellular stressors, such as excitotoxicity or reactive oxygen species. PARylated 100 
proteins can subsequently initate cellular stress response pathways.  Following resolution of the 101 
original insult, ADP-ribose polymers are rapidly removed 4,5. While PAR modification can protect 102 
the cell from death in the setting of cellular stress, excessive PAR accumulation or failure to 103 
reverse PAR modification can trigger a cell death response cascade 6,7. 104 
Humans have two genes encoding specific PAR-degrading enzymes: ADPRHL2 (MIM: 105 
610624) and PARG (MIM:603501). Both are capable of hydrolyzing the glycosidic bond 106 
between ADP-ribose moieties and are ubiquitously expressed 8,9. ADPRH (MIM:603081), and 107 
putatively ADPRHL1 (MIM:610620), encode proteins that can cleave only mono-ADP 108 
ribosylated residues and thus are not functionally redundant with ADPRHL2 and PARG 8. In situ 109 
hybridization studies showed high levels of Adprhl2 expression in the developing mouse 110 
forebrain, remaining high in cerebellum, cortex, hippocampus, and olfactory bulb in early 111 
postnatal ages, and persisting into adulthood 10. Parg knockout mice die embryonically due to 112 
PAR accumulation and cellular apoptosis 11. There are no reports of Adprhl2 knockout animals, 113 
however, Adprhl2-/- mouse embryonic fibroblasts (MEFs) engineered to express the catalytic 114 
domain of nuclear PARP1 in mitochondria, show PAR accumulation, as well as increased length 115 
of mitochondrial PAR polymers 12,13.   116 
Drosophila melanogaster has a single parg-like gene, and null flies are lethal in the larval 117 
stage, but when grown at a permissive temperature a few can survive.  The surviving flies 118 
display PAR accumulation, neurodegeneration, reduced locomotion, and premature death 14, 119 
suggesting increased neuronal vulnerability to PAR accumulation. Although mutations in PARG 120 
and PARP enzymes have not been reported in human disease, other members of this pathway 121 
 have been implicated in human phenotypes15. For example, mutations in XRCC1 (MIM:194360), 122 
a molecular scaffold protein involved in complex assembly during DNA-strand break repair, 123 
leads to PARP-1 overactivation and is associated with cerebellar ataxia, ocular motor apraxia, 124 
and axonal neuropathy 16.  125 
In this study, we show that mutations in ADPRHL2 underlie a novel, age-dependent 126 
recessive epilepsy-ataxia syndrome, initiating with sudden severe seizures in otherwise healthy 127 
individuals, followed by progressive loss of milestones, brain atrophy, and death in childhood. 128 
We describe six independent families with mutations in ADPRHL2, leading to a nearly-identical 129 
epilepsy-ataxia syndrome (Figure 1A). Only 1 of the 6 families lacked documentation of parental 130 
consanguinity (Family 2), and the parents from this family were from the same small village. The 131 
clinical details of subjects from all included families are shown in Table 1, and detailed clinical 132 
history is narrated in Document S1 in Supplemental Data. The emerging clinical picture is one of 133 
a stress-induced neurodegenerative disease of variable progression with developmental delay, 134 
intellectual disability, mild cerebellar atrophy (Figure 1B), and recurring seizures.  135 
Genome-wide linkage analysis of 14 members of Family 1 mapped the disease locus to 136 
an 11 Mb region on chromosome 1p36 with a genome-wide significant multipoint LOD 137 
(logarithm of odds) score of 3.4 (Figure S1A).  Exome sequencing of individual II-IV-6 at >30x 138 
read depth for 96.9% of the exome revealed only a single rare (AF<1:1000) potentially 139 
deleterious variant within the linkage interval: a frameshift mutation in ADPRHL2, which 140 
segregated with the phenotype according to a recessive mode of inheritance.  141 
 Using Genematcher, further pathogenic alleles in ADPRHL2 were identified by this 142 
international collaborative group of authors. By whole exome sequencing (see Supplemental 143 
Data), we have identified a total of 6 distinct mutations in ADP-ribosylhydrolase like 2 144 
(ADPRHL2, RefSeq: 54936) from the 6 families. All variants were prioritized by allele frequency, 145 
conservation, blocks of homozygosity, and predicted effect on protein function (see 146 
Supplemental Data), and in all families the homozygous variant in ADPRHL2 was the top 147 
 candidate.  Variants were confirmed by Sanger sequencing and segregated with the phenotype 148 
according to a recessive mode of inheritance. All variants were predicted to be disease-causing 149 
by the online program Mutation Taster 17. These variants were not encountered in dbGaP, 150 
ExAC, 1000 Genomes databases, genomeAD or the Middle Eastern Variome.  151 
 ADPRHL2 contains 6 coding exons, yielding a single protein-coding transcript, ADP-152 
ribosylhydrolase 3 (ARH3) (Figure 2A). The encoded 363 amino acid ARH3 protein predicted a 153 
mitochondrial localization sequence (MLS) and single enzymatic ADP-ribosyl-glycohydrolase 154 
domain (Figure 2B). Family 1 carried a homozygous mutation (c.1000C>T) in exon 6, 155 
introducing a premature stop codon (p.Gln334Ter), predicting truncation of the highly conserved 156 
last 30 amino acids of the protein, which includes part of the ADP-ribosylhydrolase domain. 157 
Family 2 harbored a homozygous mutation in exon 3 (c.316C>T), also introducing a premature 158 
stop codon (p.Gln106Ter) in the ADP-ribosylhydrolase domain. Family 3 revealed a 159 
homozygous missense mutation (c.235A>C) in exon 2, leading to an amino acid change 160 
(p.Thr97Pro) in a residue which is highly conserved among vertebrates (Figure S2A). Using a 161 
previously published crystal structure of ARH3, we localized this residue to an alpha-helical loop 162 
within the ADP-ribosylhydrolase domain and the substrate binding site, which is defined by the 163 
position of 2 Mg2+ ions located in adjacent binding sites, thus predicted to affect protein structure 164 
and enzymatic activity (Figure S2B) 18. Family 4 carried a homozygous 5 basepair (bp) deletion 165 
(c.414-418TGCCC) in exon 3, resulting in a frameshift in the ADP-ribosylhydrolase domain 166 
(p.Ala139GlyfsTer5). Family 5 carried a homozygous missense mutation (c.530C>T) in exon 4, 167 
leading to an amino acid change (p.Ser177Leu), which was also highly conserved among 168 
vertebrates. It is localized in a critical alpha-helical loop within the ADP-ribosylhydrolase 169 
domain, also suggesting an effect on protein structure and activity. Family 6 carried a 170 
homozygous missense mutation (c.100G>A) in exon 1, leading to an amino acid change 171 
(p.Asp34Asn), which was highly conserved among vertebrates. This change is also localized in 172 
 a critical alpha-helical loop within the ADP-ribosylhydrolase domain, suggesting a potential 173 
impact on protein structure and activity. 174 
  The emerging phenotype of recessive ADPRHL2 mutations is a degenerative pediatric-175 
onset stress-induced epileptic-ataxia syndrome.  Individuals with mutations in this gene are 176 
asymptomatic early after birth, but gradually develop a cyclic pattern of illness-related 177 
spontaneous epileptic seizures; or may manifest with a neurodegenerative course with 178 
weakness, ataxia and loss of milestones, followed by clinical deterioration in all individuals that 179 
ultimately may lead to premature death. Most of the subjects showed a sudden unexpected 180 
death in epilepsy or by apnoic attacks (SUDEP)-like clinical presentation, suggesting a 181 
hyperacute presentation prior to the family’s recognition of a predisposition. We could not 182 
establish an obvious genotype-phenotype correlation, however, as we show below that the 183 
missense mutation also leads to a severe loss-of-function. Thus the clinical variability in the age 184 
of onset might be due to the genetic background or environmental challenges leading to 185 
variable susceptibility to illness-related cellular stress.  186 
The differential diagnosis for this condition was based upon the presentation of a 187 
recessive condition with recurrent exacerbations showing predominant features of global 188 
developmental delay, intellectual disability, seizures, neurogenic changes on EMG, hearing 189 
impairment, regression and mild cerebellar atrophy, without microcephaly and cataracts. The 190 
differential diagnosis in our families included mitochondrial disorders, spastic ataxia, and 191 
primary peripheral neuropathy. 192 
 To determine the impact of these mutations on protein folding and binding activity, we 193 
generated recombinant proteins in E.coli, and purified by His-tag affinity chromatography. Our 194 
results showed that the p.Gln334Ter was not evident in the soluble fraction, whereas the 195 
Wildtype (WT) was recovered with good purity (Figure S3A). The p.Thr79Pro protein was 196 
expressed and soluble, possibly slightly reduced in recovery compared with the WT ARH3 197 
protein. The deleterious impact of the p.Thr79Pro variant was studied using Circular Dichroism 198 
 (CD) spectroscopy (Figure S3B-C). Compared to WT, this mutant exhibited a reduction in alpha-199 
helical content and altered secondary structure, which agreed with the fact that the p.Thr79Pro 200 
substitution occurred within an alpha-helical domain. Further, the melting temperature (Tm) of 201 
the mutant p.Thr79Pro was reduced by more than 10°C, confirming destabilization of the mutant 202 
(Figure S3D-F). We also found that, in contrast to the WT ARH3 protein, the p.Thr79Pro mutant 203 
was not stabilized by ligands such as adenosine diphosphate ribose (ADPr) (Figure S3G-I). We 204 
confirmed the specificity of this assay by using adenosine triphosphate (ATP) and ribose-5-205 
phosphate as negative controls, which were not predicted to bind or stabilize ARH3. Together, 206 
this data suggests that both disease-causing-truncating and amino-acid-substituting mutants 207 
should be destabilized when expressed in cells.  208 
Because the p.Gln334ter mutation of Family 1 was in the last exon, we first excluded 209 
nonsense mediated decay (NMD) of the mutant mRNA. We collected skin biopsies from the 210 
father (III-II) and two affecteds (II-IV-6 and II-IV-7) of Family 1, generated primary fibroblasts, 211 
then performed RT-PCR using primers designed to amplify the last 3 exons of ADPRHL2 212 
(Figure S1B). The father’s and affected individuals’ cells revealed a band of the expected size, 213 
and similar intensity to that of a healthy control, arguing against NMD. However, lysates derived 214 
from the affected individuals showed no detectable ARH3 protein (Figure 2C), using an antibody 215 
that recognizes amino acids 231-245 (see Supplemental Data), consistent with a null effect of 216 
the truncating mutation. Further, western blot analysis of individual II-2 from Family 2 shows an 217 
absence of the protein as predicted by the early stop codon; and fibroblasts from individual II-1 218 
from Family 3 showed a severe reduction of ARH3 levels (Figure 2C), consistent with the 219 
thermal instability of this mutant protein (Figure S3D-F) and the severe alteration of its 220 
secondary structure (Figure S3B-C).  221 
While humans have two known genes with specific PARG activity (PARG and 222 
ADPRHL2; Figure 3A), Drosophila have a single gene that regulates this process: parg.  Using 223 
the Gal4-UAS system to drive RNAi expression, we found that parg knockdown led to a 60% 224 
 decrease in total parg mRNA for flies with the ubiquitous da promoter and a 50% decrease with 225 
the neuron-specific promoter, elav (embryonic lethal abnormal visual system) (Figure S4A). 226 
While the da-Gal4 and pargRNAi lines showed normal survival, crossing the two together led to 227 
da-mediated expression of pargRNAi, which reduced survival substantially (Figure S4B). 228 
Ubiquitous knockdown of parg also led to decreased survival when animals were exposed to 229 
stress with either Hydrogen Peroxide (H2O2) in their water or environmental hypoxia (2% O2) 230 
(Figure S4C-D). Furthermore, knockdown of parg specifically in neurons largely recapitulated 231 
this phenotype using the same two environmental stressors (Figure S4E-F). These data provide 232 
evidence that stress leads to premature death in the absence of parg, and neurons play an 233 
important role in this phenotype.   234 
However, lethality of these flies was not as severe as in the parg27.1 line, which carries a 235 
p-element insertion that deletes two-thirds of the open-reading frame (nucelotides 34,622-236 
36,079 of Genbank Z98254) 14, suggesting that pargRNAi is only partially inactivating.  These 237 
parg loss-of-function mutant flies lack the parg protein and show elevated levels of PAR, 238 
especially in nervous tissue14.  Mutant flies die in larval stages, but ¼ of the animals survive 239 
when grown at the permissive 29°C temperature. These adult flies display progressive 240 
neurodegeneration, reduced locomotion, and reduced lifespan14, not inconsistent with the 241 
individuals’ phenotypes in our families. We confirmed lethality of the parg27.1  line and found that 242 
forced expression of Drosophila parg under the ubiquitous daughterless (da) promoter in the 243 
mutant background increased both survival and motor activity as measured by an established 244 
‘climbing index’ 19 (Figure 3B-C). Likewise, expression of the human ADPRHL2 under the same 245 
da promoter showed a nearly identical degree of rescue of both survival and locomoter activity 246 
(Figure 3B-C). These results suggest that human ADPRHL2 is a functional paralogue of 247 
Drosophila parg.  248 
We next tested whether this phenotype might be ameliorated by inhibition of protein 249 
PARylation. We reasoned that the requirement for dePARylation should be reduced by blocking 250 
 stress-induced PARylation. Minocycline displays PARP inhibitory activity, with an IC50 of 42nM 251 
in humans20 and is well tolerated in flies 21. We fed flies with a range of concentrations from 0-1 252 
mg/mL Minocycline for 24 hours prior to stress and measured survival rates at 96 hours post 253 
stress induction. Drug treatment of flies with ubiquitous knockdown of parg revealed a dose-254 
dependent partial rescue of the lethality (Figure S4G). This rescue was also seen when drug 255 
was given to flies with neuron-specific knockdown of parg (Figure S4H), providing evidence that 256 
PARP inhibition can rescue lethality in vivo. While we expect that the effect of Minocycline on 257 
survival in this assay was due to its effect on PARP, we cannot exclude off-target or non-258 
specific effects 21. 259 
Given that PARP inhibitors are currently in trials for various types of cancer, it is possible 260 
that these drugs could be tested for clinical effectiveness in this orphan disease, where they 261 
may have a positive effect. Potentially clinically relevant PARP inhibitors include: (1) 262 
Minocycline – an FDA-approved tetracycline-derivative that displays PARP inhibitory activity, (2) 263 
Dihydroisoquinoline (DPQ) – a non-FDA-approved potent PARP-1 inhibitor used in experimental 264 
research, (3) Veliparib (ABT – 888) – a potent inhibitor of PARP-1 and PARP-2 currently in 265 
clinical trials for treatment of various type of cancers (IC50 42 nM, 37 nM, 4.4 nM, respectively) 266 
20,22.  267 
The extent to which ADPRHL2 and PARG functionally diverge or converge is not well 268 
understood, based partly on a lack of detailed comparative expression analysis and biochemical 269 
function. PARG demonstrates greater specific activity than ARH3 for removing PAR from 270 
proteins 8 , and loss of Parg in mice is embryonic lethal 13. Taken together, these data suggest 271 
that PARG is likely the major contributor to PAR removal in cells that express both genes under 272 
basal conditions. One possibility is that ADPRHL2 acts as a back-up to PARG to remove 273 
excessive PAR moieties under stress conditions. This would be consistent with the clinical 274 
pesentation of individuals with loss of ADPRHL2, where phenotypes appear to be induced by 275 
environmental stress. Recent studies have shown shown that ARH3 acts on a recently 276 
 discovered, new form of Serine-ADP Ribosylation 23. For example studies illustrate an excessive 277 
accumulation of Ser-poly-ADP ribosylated enzymes in ARH3-/- cell lines, and that ARH3 acts 278 
mainly on the Ser-ADPr removal 24.  This would be consistent with the phenotype we see in 279 
subjects with loss of ARH3, where phenotypes do not emerge until environmental stress insults 280 
are encountered. Finally, only ARH3 contains a mitochondrial localization signal, and thus, 281 
another possibility is that ARH3 functions as a mitochondrial-specific glycohydrolase that is 282 
required after oxidative stress induction 25. 283 
PAR signaling has been shown to play a role in a number of cellular processes in 284 
addition to Apoptosis-inducing-factor (AIF)-mediated apoptosis, including regulation of 285 
transcription, telomere function, mitotic spindle formation, intracellular trafficking, and energy 286 
metabolism 2,3. While we hypothesize that the mechanism of disease is through cell death, it is 287 
possible that PAR accumulation may affect other cellular processes prior to this.  Further work is 288 
needed to characterize these effects in the context of this disease. 289 
 290 
 291 
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 Figure Legends 417 
 418 
Figure 1. Pedigrees of consanguineous families with mutations in ADPRHL2 and their 419 
clinical presentation.  420 
(A) Pedigrees of families 1 to 6 showing consanguineous unions (double bar) and a total of 16 421 
affected individuals. Slash represents deceased individuals. Black shading indicates affected 422 
individuals. Grey shading indicates individuals who passed away from SUDEP, however no 423 
DNA is available. (B) Panels show midline sagittal MRIs for one affected individual for each of 424 
the 6 families. White arrows: cerebellar atrophy, evidenced by widely-spaced cerebellar folia. 425 
 426 
Figure 2. Truncating and missense mutations in ADPRHL2 in five independent families 427 
predicted to be inactivating.  428 
(A) Schematic of ADPRHL2 depicting the coding sequence spanning 6 exons and the 5’ and 3’ 429 
UTRs. Black arrows indicate the positions of the five identified mutations and their coordinates 430 
within the cDNA (Refseq: 54936). (B) Schematic of ARH3 protein depicting the mitochondrial 431 
localization sequence (MLS) and the ADP-ribosyl-glycohydrolase domain. Black arrows: 432 
position and coordinates of the impact of the described mutations. (C) Western blot of 433 
fibroblasts from unrelated control (C), unaffected carrier Father (U), and affected individuals (IV-434 
II-6 and IV-II-7) from Family 1 shows absent ARH3 protein in affected fibroblasts. Alpha-tubulin: 435 
loading control. Western blot of fibroblasts from unrelated control (C) and affected individual (II-436 
1) from Family 3  and unaffected carrier mother (U) and affected individual (II-3) from Family 2 437 
shows significant reduction in ARH3 protein levels. Alpha-tubulin: loading control. 438 
 439 
Figure 3. Premature death and locomotor defects in Drosophila parg mutants rescued by 440 
human ADPRHL2.  441 
(A) Schematic of a poly-ADP-ribosylated protein and the location of cleavage. PARG and 442 
ADPRHL2 both remove poly-ADP-ribose (PAR) from proteins and cleave the same site.  443 
Drosophila melanogaster has only one PAR-removing enzyme, Parg. (B) parg27.1 mutant flies 444 
(black) show a severe climbing defect, which was rescued by ubiquitous forced expression of 445 
parg (red), or in two different transgenic lines mis-expressing human ADPRHL2 (green and 446 
blue).  (C ) parg27.1 mutant flies (black) displayed decreased survival, which was rescued with 447 
ubiquitous forced expression of parg (red) and two different transgenic lines expressing human 448 
ADPRHL2 (green and blue).   449 
 450 
Table Legend 451 
 452 
Table 1. Clinical table. 453 
Clinical presentation for affected subjects from families 1 to 6. GTCS: generalized tonic-clonic 454 
seizures. EEG: electroencephalography. MRI: magnetic resonance image. SNHL: sensorineural 455 
hearing loss. 456 
  457 
  458 
  
Family 1 Family 2 Family 3 Family 4 Family 5 
Family 6 
Individual I-IV-1 I-IV-2 I-IV-3 I-IV-5 I-IV-11 II-IV-2 II-IV-5 II-IV-6 (A1) II-IV-7 (A2) II-2 II-1 II-1 II-3 IV-1 IV-2 II-3 
Gender M F M M M F F M F M F F F M F F 
Country of Origin UAE Italy Turkey Pakistan Iran Turkey 
Parental 
Consanguinity + same village + + + + + 
Current age (if 
alive)         4 yrs       3 yrs 16 yrs 15 yrs 13 yrs 2 yrs - 3 yrs 10 yrs 
Age of death 4 yrs 2 yrs 7 yrs 15 yrs  2 yrs 2 yrs 9 yrs   - - - - 6 yrs - - 
Circumstances of 
death Died in 
sleep 
Died in 
sleep 
Had a 
seizure and 
died 
Respiratory 
failure - 
Died in 
sleep 1 
week after 
flu-like 
illness 
Playing, 
had 
seizure, 
then died 
Died after 
long trip by 
airplane of 
respiratory 
failure - - - - - 
Died in 
sleep - 
 
 
 
 
- 
Mutation                              
Genomic (hg19) g.36558895C>T g.36557226C>T g.36556868A>C g.36557324_36557328delTGCCC g.36557524C>T g.36554605G>A 
cDNA c.1000C>T c.316C>T c.235A>C c.414_418delTGCCC c.530C>T c.100G>A 
Protein p.Q334* p.Q106* p.T79P p.A139Gfs*4 p.S177L p.D34N 
Zygosity homozygous homozygous homozygous homozygous homozygous homozygous Homozygous 
Perinatal History                              
Normal birth Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Normal early 
development Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Mild 
developmental 
delay Yes Yes 
Yes 
Psychomotor 
development                              
Speech 
development 
Spoke in 
sentences, 
then 
deteriorated 
Few 
words at 
age 2 
yrs 
Normal until 
age 2.5 yrs, 
then no 
further 
development 
Normal till 
3.5 yrs, 
then 
deteriorated  
Speaks 
only few 
words 
Normal 
speech until 
death 
Normal 
speech until 
death 
Normal until 
25 yrs, then 
deteriorated 
Normal 
speech, then 
deteriorated Slow speech Normal Normal Delayed 
Normal until 
1.5 yrs, then 
deteriorated 
with 
difficulty 
speaking 
Speaks only a 
few words 
Delayed 
Motor 
development Normal, 
then 
deteriorated 
Normal 
until 
death 
Normal, then 
deteriorated 
Normal, 
then 
deteriorated 
Normal, 
then 
deteriorated 
Normal, 
then 
deteriorated 
Normal until 
death 
Normal, 
then 
deteriorated 
by age 2 yrs 
Normal, 
walked 14mos, 
then at 19mos 
poor 
balance/ataxia 
Normal, then 
deteriorated by 
age 2 yrs Normal 
Normal, then 
deteriorated 
by age 2 yrs Mildly delayed 
Normal until 
1 yr then 
deteriorated 
Normal, then 
deteriorated by 
age 1.5 yrs 
Normal 
Seizures                              
Seizure Onset 18 mos 19 mos 19 mos 24 mos 15 mos 24 mos 15 mos 18 mos 16 mos - - N/A age 9 mos 24 mos 36 mos - 
Seizure types GTCS GTCS GTCS GTCS 
Absence, 
GTCS GTCS GTCS 
Absence, 
GTCS 
Absence, 
GTCS - - 
GTCS with 
illness 
GTCS with 
illness 
Multifocal, 
GTCS 
Multifocal, 
GTCS - 
Neurological 
Examination                             
 
Intellect Normal, 
then 
delayed 
Normal 
until 
death 
Normal, then 
delayed 
Normal, 
then 
delayed 
Normal, 
then 
delayed 
Normal until 
death 
Normal until 
death 
Normal, 
then 
delayed 
Normal, then 
delayed 
Normal, then 
started 
deteriorating at 
age 11  Normal 
Mild ID (IQ 
60) 
Mild global 
developmental 
delay 
Normal, 
then 
stagnated 
Normal, then 
stagnated 
Mild ID  
EEG 
- - - - - - - 
Generalized 
epileptiform 
activity; slow 
background  
Generalized 
epileptiform 
activity; slow 
background    - 
Mild slowing 
background 
activity (3 
yrs) Normal 
Generalized 
epileptiform 
activity; 
slow 
background  Normal 
Normal 
MRI (age 
performed) 
- - - 
Normal (5 
yrs) - - - 
Mild 
cerebellar 
atrophy (7 
yrs) 
Mild cerebellar 
atrophy (7 yrs) 
Cerebellar 
vermis atrophy 
(11 yrs) 
Mild cerebellar 
atrophy and 
spinal cord 
atrophy (12 yrs) 
Mild 
cerebellar 
atrophy (4 
yrs) Normal (11mo)   Normal (3 yrs) 
Mild cerebellar 
vermis atrophy 
and  
spinal cord 
atrophy (15yrs) 
EMG/Biopsy 
- - - - - - - 
Nerve 
biopsy with 
severe 
axonal loss - - 
Axonal 
polyneuropathy 
(4yr) 
Normal 
muscle 
biopsy (4 yrs) - 
Normal at 
age 4 yrs 
Axonal 
polyneuropathy 
at 4yrs 
Axonal 
polyneuropathy 
Onset of unsteady 
gait - - 2.5 yrs 3 yrs 2.5 yrs - - 2.5 yrs 20 mos 11 yrs 4 yrs 2.5 yrs Not yet 1.5 yrs 1.5 yrs 10 yrs 
Other Clinical 
Features                             
 
Exacerbated by 
illness/stress + + + + + + + + + + + + + + + 
+ 
Other Clinical 
Features 
- - - 
Hypotonia 
with 
repeated 
pneumonia  
Can walk, 
but very 
unsteady 
Progressive 
weakness 
Progressive 
weakness 
Repeated 
pneumonia,  
repeated 
cardiac 
Normal 
hearing, then 
developed 
severe SNHL 
 Myopathic 
changes on 
muscle biopsy 
(11 yrs) 
Claw hand and 
pes cavus 
deformities, 
scoliosis, SNHL Asthma - 
Progressive 
weakness, 
tremors, 
frequent 
Progressive 
weakness and 
progressive 
external 
Distal muscle 
atrophy, pes 
cavus deformity, 
toe abnormality, 
 Ventilator 
dependent 
at time of 
death 
arrest 
Profound 
type II 
muscle fiber 
atrophy, 
Severe 
kyphoscoliosis, 
one episode of 
cardiac arrest 
at 10 yrs, 
Tracheotomy, 
ventilated 
falling ophthalmoplegia  scoliosis, brisk 
DTRs, positive 
Babinski's 
reflex, 
intentional 
tremor, ataxia 
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